MedPlus Health Services Limited has announced that its subsidiary, Optival Health Solutions Private Limited, has received a three-day suspension of its drug license for a store located in Telangana. The suspension was issued by the Drugs Control Administration for violations under the Drugs and Cosmetics Act, 1940, and related regulations. This order was received on November 8, 2025, and affects a store situated at Nagole X Roads in Telangana. The suspension is expected to lead to a potential revenue loss of approximately ₹1.73 lakhs during this period.

In compliance with the Securities and Exchange Board of India (SEBI) regulations, MedPlus has disclosed the details of this suspension to both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE), where the company is listed under the scrip code 543427 and the symbol MEDPLUS, respectively. The company indicated that further information regarding this issue will be made available on its official website as well as on the BSE and NSE websites.

The impact of this temporary suspension on MedPlus’s financial operations could be minimal, given that the revenue loss is relatively small compared to the company's overall performance. However, such regulatory setbacks can affect investor confidence and market perception. MedPlus Health Services is committed to addressing the concerns raised by the regulatory authority and ensuring compliance with all health and safety standards moving forward.